3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Sarcoma
1
Conditions
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Interventions
pembrolizumab
78
Fulvestrant
76
Carboplatin
74
Trastuzumab
71
Capecitabine
70
Letrozole
63
Cyclophosphamide
61
Paclitaxel
60
Specimen Handling
54
pertuzumab
52
Docetaxel
50
abemaciclib
46
ribociclib
45
Anastrozole
36
Magnetic Resonance Spectroscopy
35
130-nm albumin-bound paclitaxel
35
trastuzumab deruxtecan
34
Blood Specimen Collection
33
exemestane
32
Tamoxifen
32
Biopsy
32
sacituzumab govitecan
31
Gemcitabine
30
Epirubicin
29
pyrotinib
28
palbociclib
28
Drug Therapy
28
Surveys and Questionnaires
27
Injections
27
eribulin
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
SGN-LIV1A
×
Breast
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT03424005
2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2
Recruiting
792 enrolled